ABSTRACT
OBJECTIVE: To evaluate the performance of BNII auto-analyzer system in detecting C3 and C4. METHODS: CLSI protocols (EP15-A, EP6-A, EP9-A2) and other relevant literatures were use to or evaluate the precision, accuracy, linearity of C3 and C4 detection by the auto-analyzer system, and the results were compared with the recognized standards. RESULTS: The relative bias of C3 and C4 was less than one third of the CLIA'88 standard and the precision met the clinical requirement. The results tested by DADE BNII system were not compatible with those by Roche Modular System. C3 showed good linearity in the tests (R2>0.975, P<0.05) with a linearity range of 0.18-5.1 g/L. The linearity of C4 was not available because of lack of high-level samples. CONCLUSION: The performances of DADE BNII System basically meet the recognized standards in clinical detection of C3 and C4, but the method comparison needs further validation.
Subject(s)
Blood Chemical Analysis/methods , Complement C3/analysis , Complement C4/analysis , Autoanalysis/methods , Blood Chemical Analysis/instrumentation , Humans , Nephelometry and Turbidimetry/instrumentation , Nephelometry and Turbidimetry/methods , Proteins/analysis , Sensitivity and SpecificityABSTRACT
OBJECTIVE: To investigate the relationship between HBV lamivudine resistance and HBV genotypes or basic core promoter (BCP) mutations. METHODS: The common coated probes were synthesized according to the conserved regions of the preC gene of hepatitis B virus (HBV). Different colorized probes were chosen from the sequences of different genotypes of HBV (A to F), BCP and YMDD wild types and mutants, respectively. HBV DNA levels, HBV genotypes, BCP and YMDD resistants were analyzed by PCR microplate hybridization ELISA at the zero and 6th month after the patients were treated with lamivudine. RESULTS: HBV genotyping results showed that HBV types B, C, D accounted for about 30%, 36% and 23% patients respectively. Thirteen BCP mutations (type B in 1 patient, type C in 8 and type D in 4) were found before treatment with lamivudine. HBV DNA levels were lower than 100 pg/ml in 2 patients and higher than 100 pg/ml in 11. 9.4% of the HBV patients (5/43; type C in 3 and type D in 2) showed YMDD resistants and 4 BCP mutations at the same time. CONCLUSION: Oral treatment of lamivudine decreases the level of serum HBV DNA. The appearance of HBV YMDD resistants is related to certain HBV genotypes, and most of them are BCP mutations.
Subject(s)
Antiviral Agents/pharmacology , Drug Resistance, Viral/genetics , Hepatitis B virus/genetics , Lamivudine/pharmacology , Base Sequence , China , Drug Resistance, Viral/drug effects , Genotype , Hepatitis B virus/drug effects , Humans , Molecular Sequence Data , Mutation/geneticsABSTRACT
OBJECTIVE: To observe IgG and IgM antibodies in patients with severe acute respiratory syndrome (SARS) and to explore their significance. METHODS: IgG and IgM antibodies were detected in SARS Patients in the first, recovery and follow-up stages, the front healthy doctors and nurses and healthy volunteers with indirect enzyme-linked immunoadsorbent assay. RESULTS: The positive ratio of IgG was higher than that of IgM in SARS patients during the first stage. During the recovery, follow-up stages and in the front healthy crowd, the positive ratios of IgG were all higher than those of IgM. CONCLUSION: The changeable tendency SARS antibody is more different than that of other infectious diseases. This tendency can be used as a indicator for epidemiological study and serum diagnose.
Subject(s)
Antibodies, Viral/blood , Immunoglobulin G/blood , Immunoglobulin M/blood , Severe Acute Respiratory Syndrome/immunology , Severe acute respiratory syndrome-related coronavirus/immunology , Female , Humans , MaleABSTRACT
OBJECTIVE: To identify the impact of lamivudine on HBV e antigen (HBeAg) seroconversion and HBV DNA level, and the appearance of Tyr-Met-Asn-Asp (YMDD) resistants. METHODS: Forty-seven hepatitis B patients were treated with oral lamivudine. ALT level and HBeAg were detected in the treatment on the zero, 3rd, 6th and 9th month respectively. The levels of HBV DNA and YMDD resistants were analyzed with PCR microplate hybridization-ELISA. RESULTS: After 9 months of treatment, HBV DNA became negative and ALT level was normal in 74% patients. Among these patients, 17% patients had HBeAg converted to negative and anti-HBe antibody positive, whereas another 15% patients showed HBeAg negative. YMDD resistants appeared in 19% patients (9/47). One, three and five resistants were detected in the treatment on the 3rd, 6th and 9th month respectively. CONCLUSIONS: Most HBV DNA in serum became negative after 9 months of treatment, and the rate of HBeAg seroconversion was 17% (HBV DNA level was lower than 100 pg/ml before treatment). YMDD resistants appeared in 19% patients.
